Sjögren's Syndrome Diagnosis and Management

Introduction to Diagnosis

Sjögren's syndrome diagnosis involves considering serological markers (Anti-SSA/Ro and anti-SSB/La antibodies), objective measures (ocular and oral dryness tests), and clinical symptoms (documented sicca symptoms), as recommended by the American College of Rheumatology 1

The lower lip is the recommended site for minor salivary gland biopsy, with a minimum of four labial salivary glands required to ensure adequate tissue sampling and diagnostic accuracy, providing a minimum glandular surface area of 8 mm² 1
Minimally invasive techniques result in fewer permanent complications (0.17% permanent complication rate) compared to conventional linear incision approaches (1.45% permanent complication rate) 1
Patients should be informed about the 4% risk of temporary numbness and the rare risk of permanent complications (0.17-1.45% depending on technique), as well as the diagnostic value of the procedure, particularly for patients without clear serological markers 1

A focus score ≥1, which relies on counting aggregates of ≥50 mononuclear cells per 4 mm² of glandular tissue, is considered diagnostic for Sjögren's syndrome by the American College of Rheumatology 1
The European League Against Rheumatism suggests obtaining sufficient tissue (minimum of four labial salivary glands) and using standardized focus score calculation methods to minimize misinterpretation 1
The use of immunosuppressive medications like mycophenolate or prednisone for more than 6 weeks prior to biopsy may significantly affect results, according to the American College of Rheumatology 1
Patients with both sicca symptoms and positive serology have a higher likelihood (75%) of positive biopsy results, even without medication interference, as suggested by the European League Against Rheumatism 1

Common pitfalls in diagnosis include ignoring medication history, relying solely on biopsy, inadequate sampling, and inconsistent scoring, and the American College of Rheumatology recommends documenting immunosuppressive medication use and using multiple diagnostic criteria 1
Pathologic misinterpretation occurs in approximately 10% of specimens, with incorrect application of grading systems in up to 45% of cases, highlighting the need for standardized application of focus score calculation, as recommended by the American College of Rheumatology 1
For patients who cannot discontinue immunosuppressive medications due to other medical conditions, it is essential to document the dosage and duration of treatment when submitting the biopsy, and to place greater emphasis on other diagnostic criteria, including serological markers, objective measures of ocular and oral dryness, and clinical symptoms 1